The study on the efficacy of intraperitoneal administration of triamcinolone acetonide to cancerous ascites in end-of-life patients

The study on the efficacy of intraperitoneal administration of triamcinolone acetonide to cancerous ascites in end-of-life patients - The study on the efficacy of intraperitoneal administration of triamcinolone acetonide to cancerous ascites in end-of-life patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034123

Enrollment

Registered

2018-09-14

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

Patients are evaluated their symptoms using ESAS-J and STAS-J at the time of ascites removal (1st course: day 0). They are evaluated their symptoms again using ESAS-J and STAS-J 3 days after ascites r

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Cancer patients in hospital. 2.Medical adaptation for ascites removal. 3.There is hope of removing ascites from the patient. 4.Triamcinolone acetonide intraperitoneal administration not yet experienced. 5.Consent can be acquired in writing or verbal. 6.Cognitive function is enough to respond to survey forms.

Exclusion criteria

Exclusion criteria: Patients that do not satisfy the above selection criteria.

Design outcomes

Primary

Measure	Time frame
The duration of ascites removal	—

Secondary

Measure	Time frame
Variations of symptoms before and after removal of ascites	—

Countries

Japan

Contacts

Public ContactNiki Kazuyuki

Osaka University/Ashiya Municipal Hospital Graduate School of Pharmaceutical Sciences/Department of Pharmacy

k-niki@phs.osaka-u.ac.jp06-6879-8250

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026